Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 3/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330274 | 0.85 | LMNA (0.69) | LMNAHTTTP53P2RX7PKM | |
| Iodide SCHEMBL14739705 | 0.85 | SLC2A1 (0.47) | LMNAHTTTP53P2RX7TLR8 | |
| SCHEMBL31066875 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL31066882 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL9274775 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL20242949 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL17053182 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL2943250 | 0.80 | TLR8 (0.70) | LMNAHTTTP53P2RX7PKM | |
| SCHEMBL8273589 | 0.79 | LMNA (0.61) | LMNAHTTTP53P2RX7PKM | |
| Hydrochloric Acid SCHEMBL8158771 | 0.79 | TLR8 (0.68) | LMNAHTTTP53PKMTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298841-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2019-10-03 | — | — | US | disclosed |
| US-10350299-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD. (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9669101-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9550991-B2 | Transcription factor decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-01-24 | — | — | US | disclosed |
| EP-2552455-B1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350299-B2 | Nucleic acid complexes | ZFR, SUB1, RELA | LMNA 1170/4885HTT 1326/4885TP53 1077/4885 |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | LMNA 1170/4885HTT 1326/4885TP53 1077/4885 |
| US-20190298841-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | LMNA 1170/4885HTT 1326/4885TP53 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.